Evogene Ltd.

EVGN Healthcare Biotechnology

In the quarter to June 2026, revenue fell 35.0%, EPS grew 77.4% and free cash flow grew 17.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

0.39 0.01 −2.50%
Market cap
$6.3M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
4/9
Altman Z
−20.48
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
3.24 4.07 2.25 4.45
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(2.72) (2.54) (3.22) (2.98)
P/B ratio
0.93 0.94 0.72 0.58
EV/Sales
(2.40) (3.03) (1.12) (2.70)
EV/EBITDA
0.37 0.54 0.37 0.61
EV/FCF
0.37 0.50 0.32 0.38
Current Ratio
3.57 2.79 4.54 5.11
Net Debt/EBITDA
3.85 10.62 2.56 7.91
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(206.82%) (180.52%) (106.36%) (43.86%)
Free Cash Flow Yield
(200.84%) (149.22%) (156.55%) (158.98%)
Free Cash Flow per Share
(0.16) (0.30) (0.34) (0.38)
Book value per Share
0.47 0.82 1.52 1.98
Free Cash Flow
(1.89) (2.93) (2.64) (3.31)
EV/EBIT
0.28 0.39 0.31 0.48
Other line items

Show all line items

Columns are period end dates